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Abstract: Prostate cancer is the most common cancer in men and therefore represents a major problem 
in public health.The aim of this study was to find and evaluate province-specific estimate
 of incidence 
in males by age groups
 for prostate cancer in Golestan province, Iran. The data used in this study were 
collected in a cancer registry program that was conducted by Health Deputy of Golestan province in 
IRAN for a period of 1 year (2004). Prostate cancer data was identified and collected in the population 
based cancer registries through the 18 Pathology Laboratories (where male populations referred to 
these centers) and using a structured questionnaire, trained personnel conducted
 in-person interviews to 
collect information on prostate cancer in Golestan province. Prostate cancer incidence among males in 
Golestan province was 5.17/100000 in gerenal. But the highest rate (ASR: 215.87/100,000) among 
males were showen to be in age 80-85. The incidence of prostate cancer in age 80-84 has risen sharply 
and  it  was  the  lowest  in  age  50-54  (ASR:  5.18/100,000).  According  to  this  information  Golestan 
province  harbor  a  rather  incidence  for  prostate  cancer  (in  age  80-84),  comparable  to  the  lower 
incidence rate reported in the world. For the present time it can be said that prostate cancer in males 
appear to be one of the most prevalent and serious type of cancer in Golestan province. 
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INTRODUCTION 
 
At  present,  cancer  is  a  serious  public  health 
problem  in  many  countries  of  the  world,  imposing  a 
large economical and psychological burden as well as 
loss of life and productivity
[1]. Lots of effort and money 
have been put in the fields of clinical, epidemiological, 
pharmacological, and biological research on cancer in 
the recent decades. Cancer is the third most common 
cause of death in Iran and annually 30000 of Iranian die 
due to cancer
[2]. It is estimated that more than 70000 
new  cases  of  cancer  occur  in  the  country  and  it  is 
estimated  that  the  cancer  incidence  in  next  decade 
suspected  to  be  increased  due  to  increase  in  elderly 
population within the country 
[3]. Prostate cancer is the 
second  leading  cause  of  male  cancer  death
  in  most 
industrialized  countries  [4].It  is  the  most  common 
cancer diagnosed among men
 in the United States. In 
2005, an estimated 232,090 new cases
 diagnosed and 
30,350 men will die from prostate cancer
 in the United 
States 
[5]. African-Americans have the highest
 reported 
rates of prostate cancer in the world (With a worldwide 
incidence  of  25.3  per  100,000),  with  an  age-adjusted 
rate of 137 per 100,000, which is 60 times higher than 
the  reported  incidence  in  Shanghai,  China,  where the 
reported  incidence  is  the  lowest  in  the  world  (2  per 
100,000)
[6-7].The  distribution  of  cancers  vary 
significantly from country to country all
 over the world. 
The  latest  estimates  of  global  cancer  incidence
  show 
that prostate cancer is the sixth most common cancer in
 
the world, the third most common
 cancer in men, the 
most common cancer in men in Europe, North
 America, 
and some parts of Africa with half a million new cases
 
each  year,  almost  10%  of  all  cancers  in  men 
[8-10]. 
Prostate
  cancer  incidence  is  characterized  by  a  very 
large  geographical
  variability.  Asian  countries  have 
much  lower  rates  of  occurrence
  of  the  disease  than 
North  American,  and  north  and  western  European
 
countries, with southern European and South American 
countries
  displaying  an  intermediate incidence rate
[11]. 
Japanese  and  Chinese  men  are  less  likely
  to  develop 
prostate  cancer 
[12].  The  incidence  of  prostate  cancer 
was  lowest  among  Asians  (Japanese,  39/100  000
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years)
[13].  Cancer
  registries  are  available  in  many 
countries, but it is important
 to note that the degree of 
accuracy may vary. In many countries
 cancer registries 
have  only  recently  been  established  and/or
  may  not 
cover the whole country, this may explain the low rates
 
of  cancer  in  some  reports  [14].  In  Italy  and  Spain, 
prostate
  cancer  incidence,  according  to  estimates  in 
2000, was ranked
 third (approximately 10% of all new 
diagnosed  cancers),  while
  in  France  it  was  the  most 
common  male  cancer  (approximately
  19%)  [15].This 
study was a province-specific estimate
 of incidence by 
age groups
 for prostate cancer in the year 2004.  
 
MATERIALS AND METHODS 
 
 The  data  used  in  this  study  were  collected  in  a 
cancer registry that was conducted by Health Deputy of 
Golestan  province  in  IRAN  for  a  period  of  1  year 
(2004). This article focuses on the male cancer registry. 
Golestan  province  is  located  in  north  of  Iran,  in  the 
south east of Caspian Sea. The male cancer registry of 
the Golestan province for different cancer was 409. The 
collected  data  included  population  distribution  by 
gender (male) and age, divided into five-year intervals. 
The  age  distribution  was  collected  according  to  the 
following age strata: 0-4, 5-9, 10-14, 15-19, 20-24, 25-
29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 
65-69,  70-74,  75-79,  80-84  and  85  above.  Prostate 
cancer  data  was  identified  and  collected  in  the 
population  based  cancer  registries  through  the  18 
Pathology  Laboratories  (where  male  populations 
referred  to  these  centers)  and  using  a  structured 
questionnaire,  trained  personnel  conducted
  in-person 
interviews to collect information on prostate cancer. in 
the  Golestan  province.  These  were  then  sent  to  the 
Cancer  Registry  Office  of  the  province  and  to  the 
cancer registry unit in the Health Deputy. Age-specific 
rates,  annual  age-adjusted  rates  (ASRs)  per  100,000 
person-years were calculated using the direct methods 
of  standardization  to  the  world  population.  The  data 
were summarized in a data sheet and coded using the 
ICD-O. The data were recorded at different levels due 
to a need for correct registration. This has been done by 
iarccrgtools-203 software, because it could control the 
probable problems due to registration at different level. 
 
RESULTS 
 
        A total of 409 males cancer registry from all sites 
were captured during the one year period, 2004. From 
this  28    cases  were  prostate  cancer  .Prostate  cancer 
incidence rates vary by age .The highest prostate cancer 
incidence  among  males  in   Golestan province was in 
age 80-84 ( ASR: 215.87/100,000).The prostate cancer 
incidence according to age specific was as follow: in 
ages : in ages 0-4,  5-9, 10-14 , 15-19 , 20-24, 25-29, 
30-34 , 35-39 , 40-44 and 45-49   no prostate cancer 
incidence(ASR:  0.00/100,000),  in  age  50-54  (ASR: 
5.18/100,000),  in  age  55-59  no  prostate  cancer 
incidence  (ASR:  0.00/100,000),  in  age  60-64 
(ASR:10.62/100,000),  in  age  65-69  (ASR: 
18.31/100,000), in age 70-74 (ASR: 107.32/100,000) in 
age 75-79  (ASR: 70.96/100,000), in age 80-84 ( ASR: 
215.87/100,000) and in age above 85 no prostate cancer 
incidence  (ASR:  0.00/100,000).  The  incidence  of 
prostate cancer in age 80-84 has risen sharply and in 
age 50-54 incidence of prostate cancer was the lowest 
(ASR:  5.18/100,000).  All  diagnosed  prostate  cancer 
was adenocarcinoma. 
 
DISCUSSION 
 
This study presents data and discusses age specific 
prostate  cancer  incidence  of  the  numbers  of
  people 
diagnosed  with  cancer.  The  findings  of  this  study 
showed that prostate cancer is one of the most common 
cancers  in  the  Golestan  province  among  males.  The 
registry showed that the annual ASR for prostate cancer 
was 5.17 per 100000 populations in Golestan province. 
Prostate  cancer  is  a  disease  predominantly
  affecting 
elderly men, and, despite the widespread use of PSA 
(prostate specific antigen)
 testing in many countries, the 
number  of  deaths  from
  prostate cancer has increased. 
Compared with most cancers, prostate cancer tends to 
grow  slowly.
  The  prostate  cancer  is  the  fifth  most 
common  cancer  in  the  world
  and  the  second  most 
common in men (19% in developed countries and 5.3% 
in developing countries).
 Three-quarters of all cases
 are 
in men aged 65 or more [16]. Comparison of the ASR 
for  prostate  cancer  (age  specific)  among  males  in 
Golestan  province  with  those  of  prostate  cancer 
worldwide  show  that  the  Golestan  province  is  also  a 
risk areas like other places in the world. we found that 
the incidence of prostate cancer rises from age 50 years 
old (ASR: 5.18/100,000) and is highest in 80-84 years 
old (ASR: 215.87/100,000). Hsing et al. [6] reviewed 
data on international trends in prostate
 cancer incidence 
and mortality. In the United States, they
 observed the 
largest  increases  in  incidence  in  high-risk  countries,
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effect
 of increasing detection of prostate cancer due to 
use of PSA (prostate specific antigen). But there
 were 
also large increases in low-risk countries between 1975
 
and 1990: 104% in Singapore, China; 84% in Miyagi, 
Japan;  55%
  in  Hong  Kong;  and  44%  in  Shanghai, 
China. Some of this may be due to greater awareness of 
the disease, and diagnosis
 of small and latent cancers. 
The early diagnosis of prostate cancer maybe effective 
to prevent the progress of this cancer. A number of risk 
factors  have  been  identified
  for  prostate  cancer.  The 
most important
 risk factors are age and
 risk increases 
with age. Very few cases are registered in men under 50 
and more than 60% of cases occur in men over 70 years 
old. The largest number of cases is diagnosed in those 
aged 70–79
[17-20]. After controlling for age, the greatest
 
increase  in  risk  has  generally  been  associated  with  a 
family
 history of prostate cancer. Risk increases two to 
three  times  for  men with a family history of prostate 
cancer in a first-degree relative 
[11]. The high rates of 
prostate  cancer  have  been  associated  with  the  high 
intake  of  animal  fat 
[21-22].  Clinicians  should  follow 
recommended screening guidelines and encourage their 
patients before age 50 and older (in this area) to have 
annual
  PSA  testing.  The  reason  for  high  incidence 
report in some countries is the use of PSA screening 
test. On the other hand this report which is explained in 
methodology  is  only  focused  on  the  registered  cases 
and this can influence in the reported prostate cancer. 
Clinicians should also ensure
 that patients at high risk 
for  prostate  cancer  are  identified
  and  offered 
appropriate referrals and treatment. Continued
 research 
is needed on the causes, prevention, and treatment
 of 
prostate cancer. In this area the incidence of prostate 
cancer is started from age 50 years old onward. The age 
specific prostate cancer maybe is one of the main cause 
of  cancer  deaths  in  Golestan  province.  According  to 
this  information  Golestan  province  harbor  a  rather 
incidence for prostate cancer (age specific), comparable 
to the lower incidence reported in the world.  
 
CONCLUSION 
 
For  the  present  time  it  can  be  said  that  prostate 
cancer in males appear to be one of the most prevalent 
and serious type of cancer in Golestan province and is 
rising  with  ageing.  Thoughtfully  designed 
epidemiological  and  clinical  studies  are  pivotal  to 
unravel the details of why and how these are happening 
and  help  to  plan  what  should  be  done  to  combat 
effectively with these still deadly diseases. Therefore, 
further studies to look for the etiology and possible risk 
factors seem logical. 
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